Metabolomics reveal 1-palmitoyl lysophosphatidylcholine production by peroxisome proliferator-activated receptor α

• DOI: 10.1194/jlr.m052464
• Publication Date: 2014-12-16T05:31:21Z
• Authors: Haruya Takahashi; Tsuyoshi Goto; Yota Yamazaki; Kosuke Kamakari; Mariko Hirata; Hideyuki Suzuki; Daisuke Shibata; Rieko Nakata; Hiroyasu Inoue; Nobuyuki Takahashi; Teruo Kawada
• Keywords: Lysophosphatidylcholine; PPAR agonist

PPARα is well known as a master regulator of lipid metabolism. activation enhances fatty acid oxidation and decreases the levels circulating cellular lipids in obese diabetic patients. Although target genes are widely known, little about alteration plasma liver metabolites during activation. Here, we report that metabolome analysis-implicated upregulation many lysoGP species bezafibrate (PPARα agonist) treatment. In particular, 1-palmitoyl lysophosphatidylcholine [LPC(16:0)] increased by treatment both liver. mouse primary hepatocytes, secretion LPC(16:0) on activation, this effect was attenuated antagonist We demonstrated Pla2g7 gene expression murine hepatocytes were suppressed siRNA Interestingly, activates induces hepatocytes. Furthermore, showed has ability to recover glucose uptake adipocytes induced insulin resistance. These results reveal hepatocytes; contributes recovery insulin-resistant adipocytes.